| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004854289 |
| P356 | DOI | 10.1007/S13277-016-5381-7 |
| P698 | PubMed publication ID | 27639383 |
| P2093 | author name string | Chen Zhang | |
| Bingfei Xu | |||
| Pian Liu | |||
| P2860 | cites work | Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis | Q37360125 |
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor | Q37517706 | ||
| CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies | Q37960157 | ||
| Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. | Q38381981 | ||
| Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways | Q38785774 | ||
| Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms | Q38852858 | ||
| Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q39226360 | ||
| Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor | Q39294580 | ||
| Cancer statistics in China, 2015. | Q40064386 | ||
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 | ||
| A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | Q41699326 | ||
| Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. | Q41791633 | ||
| Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. | Q46011005 | ||
| Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? | Q51912002 | ||
| Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. | Q54300242 | ||
| Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors | Q58614417 | ||
| Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase | Q73466868 | ||
| Should individual PI3 kinase isoforms be targeted in cancer? | Q24309044 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Nicotine-induced resistance of non-small cell lung cancer to treatment--possible mechanisms | Q26768163 | ||
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor | Q27676347 | ||
| Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis | Q27851848 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| ShcA signalling is essential for tumour progression in mouse models of human breast cancer | Q28590157 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors | Q33420634 | ||
| PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context | Q33674643 | ||
| The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type | Q34262144 | ||
| Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy | Q34745118 | ||
| The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation | Q35133782 | ||
| Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent | Q36062493 | ||
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 | ||
| PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers | Q36840275 | ||
| PTEN-deficient cancers depend on PIK3CB. | Q36861839 | ||
| PI3K pathway dependencies in endometrioid endometrial cancer cell lines | Q36980561 | ||
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 14831-14839 | |
| P577 | publication date | 2016-09-17 | |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer | |
| P478 | volume | 37 |
| Q99408601 | Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations |
| Q42654081 | PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation |
| Q64075558 | PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction |
Search more.